Gutiérrez Sonia, Guillemi Silvia, Jahnke Natalie, Montessori Valentina, Harrigan P Richard, Montaner Julio S G
BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.
Clin Infect Dis. 2008 Feb 1;46(3):e28-30. doi: 10.1086/525857.
We summarize the clinical history and laboratory results following the introduction of tenofovir among 6 patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who presented with severe liver disease while receiving lamivudine-based highly active antiretroviral therapy. In all cases, the introduction of tenofovir led to a sustained undetectable HBV and HIV loads, with marked clinical and laboratory improvement in liver function. We provide supporting evidence for the role of tenofovir in the management of advanced HBV infection in HIV-positive patients after the development of lamivudine resistance.
我们总结了6例同时感染人类免疫缺陷病毒（HIV）和乙型肝炎病毒（HBV）的患者在接受基于拉米夫定的高效抗逆转录病毒治疗时出现严重肝病后引入替诺福韦的临床病史和实验室检查结果。在所有病例中，引入替诺福韦后乙肝病毒（HBV）和艾滋病毒（HIV）载量持续检测不到，肝功能在临床和实验室检查方面均有显著改善。我们为替诺福韦在拉米夫定耐药后对HIV阳性患者晚期HBV感染管理中的作用提供了支持性证据。
